Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Ferraro

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis and Related Disorders|December 30, 2022
Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH studyFrancesco Patti, Clara Grazia Chisari, Simona Toscano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2025
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 19, 2020
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsPietro Iaffaldano, Giuseppe Lucisano, Francesco Patti, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Journal of Neurology|November 3, 2023
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster doseMassimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Multiple Sclerosis and Related Disorders|November 4, 2019
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre studyDiana Ferraro, Pietro Annovazzi, Marcello Moccia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2022
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapiesIrene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 2, 2022
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective studyMatteo Gastaldi, Thomas Foiadelli, Giacomo Greco, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis and Related Disorders|December 30, 2022
Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH studyFrancesco Patti, Clara Grazia Chisari, Simona Toscano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2017
Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisTomas Kalincik, Vilija Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 19, 2025
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Neurology|August 11, 2017
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G Jokubaitis, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 19, 2020
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factorsPietro Iaffaldano, Giuseppe Lucisano, Francesco Patti, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Journal of Neurology|November 3, 2023
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster doseMassimiliano Di Filippo, Diana Ferraro, Paolo Ragonese, et al.
Multiple Sclerosis and Related Disorders|November 4, 2019
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre studyDiana Ferraro, Pietro Annovazzi, Marcello Moccia, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 23, 2022
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapiesIrene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 2, 2022
Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective studyMatteo Gastaldi, Thomas Foiadelli, Giacomo Greco, et al.
Pageof 13